According to a panel that featured NPC Chief Science Officer Robert W. Dubois and was summarized in a Value in Health article, even though value assessment frameworks are growing in use, these cost-effectiveness measurement tools are not ready for “prime time” as they leave out critical considerations, including the patient voice. 

A white paper from NPC and Discern Health analyzes the landscape of available patient-reported measures and patient-reported performance measures in oncology, and offers recommendations for filling gaps in measures and removing barriers to measure implementation in accountable care programs.

In his latest column for Specialty Pharmacy Times, NPC President and CEO Dan Leonard explores recent research that found biopharmaceuticals provide substantial health care benefits at modest cost for six of the top seven conditions causing death and mortality between 1995 and 2005, providing powerful proof with which to challenge the conventional wisdom that all health care spending is out of control.